HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With OTC Cialis Rights, Sanofi Launches Latest Salvo In Consumer Sector Battle

This article was originally published in The Tan Sheet

Executive Summary

Sanofi gains rights from Eli Lilly & Co. to apply for OTC approval of Cialis in the U.S., Europe, Canada and Australia. Launching the first OTC product indicated for erectile dysfunction would mark another milestone in Sanofi CEO Chris Viebacher’s mission to move the firm into the neighborhood of global OTC leaders.

You may also be interested in...

Sales & Earnings In Brief

Merck consumer slips; Sanofi touts diversity; Bayer’s eye on the prize; incentives, China slow USANA growth; Ukraine changes cost Mannatech; vitamins strengthen Church & Dwight.

Teva’s Generic Viagra Launch Will Be Offset By Generic Cialis

Patent settlement will enable Teva to enter the market more than three years before Viagra’s use patent expires; Pfizer suddenly parts ways with General Counsel Amy Schulman.

Pfizer Pulls Back On European Viagra Switch As Questions Linger

Pfizer withdraws its application to switch Viagra 50 mg from prescription to nonprescription status through the European Medicines Agency's centralized process, the company said Nov. 20

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts